For laboratory / research use only — not for human consumption. Read full disclaimer.

Calculator

Advanced Peptide Dosage Calculator

Convert subject bodyweight, target dose (absolute or mcg/kg), vial size and bacteriostatic-water volume into the exact draw volume and U-100 / U-50 syringe ticks for any research peptide.

Inputs

kg
mcg/kg

Typical research range: 1 – 10 mcg/kg for healing peptides.

mg
mL

Results

Target dose

400 mcg

Concentration

2500 mcg/mL

Draw volume

0.160 mL

Ticks on U-100

16.0

Doses per vial

~12

Bodyweight

80.0 kg

Calculations assume a U-100 (100 units = 1 mL) or U-50 (50 units = 0.5 mL) insulin syringe. Verify concentration with your laboratory's analytical instrumentation. For research use only.

How this calculator works

The dosage calculator combines two well-established laboratory conversions. First, it derives the peptide concentration from the mass in the vial and the volume of bacteriostatic water used to reconstitute it: concentration (mcg/mL) = vial mass × 1000 ÷ BAC water volume. Second, it derives the required draw volume for the desired dose: volume (mL) = target dose ÷ concentration. The number of ticks on an insulin syringe is then volume × 100 for both U-100 (1 mL = 100 ticks) and U-50 (0.5 mL = 50 ticks) presentations.

Bodyweight-scaled dosing

Many healing-class peptides — including BPC-157 and Thymosin Beta-4 (TB-500) — are researched at dose ranges expressed in micrograms per kilogram of bodyweight, typically between 1 and 10 mcg/kg. The calculator multiplies subject weight (after converting from pounds if necessary) by your selected mcg/kg value to derive the absolute dose, then carries that forward through the volume conversion.

Assumptions

  • U-100 insulin syringe: 100 marked ticks = 1 mL.
  • U-50 insulin syringe: 50 marked ticks = 0.5 mL (the markings have the same scale but the body holds half the volume).
  • Concentration is uniform — gentle vial inversion is sufficient; never shake.
  • The reference range shown beneath the dose input reflects published research-stage protocols for the selected peptide.

Supporting research

  • Sikiric P et al., The pharmacological properties of the novel peptide BPC 157 (PL-10), Inflammopharmacology, 1993.
  • Goldstein AL et al., Thymosin β4: actin-sequestering protein moves to centre stage of medical sciences, Br J Cancer, 2005.
  • Falutz J et al., Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients, NEJM, 2007.
  • Wilding JPH et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity, NEJM, 2021.

Related tools